ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -9 مورد

Erythromycin and benzoyl peroxide: Drug information

Erythromycin and benzoyl peroxide: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Erythromycin and benzoyl peroxide: Patient drug information" and "Erythromycin and benzoyl peroxide: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Benzamycin
Brand Names: Canada
  • Benzamycin
Pharmacologic Category
  • Acne Products;
  • Topical Skin Product, Acne
Dosing: Adult
Acne vulgaris

Acne vulgaris: Topical: Apply twice daily, morning and evening.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Erythromycin and benzoyl peroxide: Pediatric drug information")

Acne vulgaris

Acne vulgaris: Note: Guidelines recommend as monotherapy for mild acne or in combination with topical retinoids or systemic antibiotics for moderate to severe acne (Ref).

Children ≥7 years and Adolescents: Limited data available in <12 years (Ref): Topical: Apply to affected area(s) twice daily, in the morning and in the evening.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Also see individual agents.

1% to 10%: Dermatologic: Urticaria (3%), xeroderma (3%)

Postmarketing:

Dermatologic: Oily skin, skin discoloration, skin irritation (including burning sensation of skin, dermatitis [face, eyes, nose], desquamation, erythema of skin, pruritus), skin tenderness

Ophthalmic: Eye irritation

Contraindications

Hypersensitivity to erythromycin, benzoyl peroxide, or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Bleaching effects: May bleach hair or colored fabric.

• Skin irritation: Discontinue use if severe skin irritation or redness occurs.

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment. Stop the drug if significant diarrhea occurs.

Concurrent drug therapy issues:

• Sulfone products: Concomitant use of benzoyl peroxide with sulfone products (eg, dapsone, sulfacetamide) may cause temporary discoloration (yellow/orange) of facial hair and skin. Application of products at separate times during the day or washing off benzoyl peroxide prior to application of other products may avoid skin discoloration (Dubina 2009).

• Topical acne products: Use concomitant topical acne therapy with caution; cumulative irritancy may occur.

Other warnings/precautions:

• Appropriate use: For external use only; avoid contact with mucous membranes and eyes.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Gel, External:

Benzamycin: erythromycin 3% and benzoyl peroxide 5% (46.6 g) [contains alcohol, usp]

Generic: erythromycin 3% and benzoyl peroxide 5% (23.3 g, 46.6 g)

Generic Equivalent Available: US

Yes

Pricing: US

Gel (Benzamycin External)

5-3% (per gram): $1.61

Gel (Benzoyl Peroxide-Erythromycin External)

5-3% (per gram): $8.54 - $8.90

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Gel, External:

Benzamycin: erythromycin 3% and benzoyl peroxide 5% (46.6 g) [contains alcohol, usp]

Administration: Adult

Topical: For external use only; avoid applying to inside nose, mouth, eyes, and mucous membranes. Apply to clean, dry skin. Wash hands before and after use.

Administration: Pediatric

Topical: For external use only; avoid applying to inside nose, mouth, eyes, and mucous membranes. Wash hands before and after use. Skin should be clean and dry before applying. May bleach hair or fabric.

Use: Labeled Indications

Acne vulgaris: Topical treatment of acne vulgaris.

Metabolism/Transport Effects

Refer to individual components.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Aminolevulinic Acid (Systemic): Photosensitizing Agents may increase photosensitizing effects of Aminolevulinic Acid (Systemic). Risk X: Avoid

Aminolevulinic Acid (Topical): Photosensitizing Agents may increase photosensitizing effects of Aminolevulinic Acid (Topical). Risk C: Monitor

Clindamycin (Topical): Erythromycin (Topical) may decrease therapeutic effects of Clindamycin (Topical). Management: Consider avoiding use of topical erythromycin and topical clindamycin at the same application site when treating acne vulgaris. This recommendation does not appear to apply to intravaginal use of clindamycin for the treatment of bacterial vaginosis. Risk D: Consider Therapy Modification

Dapsone (Topical): Benzoyl Peroxide may increase adverse/toxic effects of Dapsone (Topical). Specifically, the use of these agents in combination may cause skin and facial hair to temporarily turn a tan or yellow/orange color. Risk C: Monitor

ISOtretinoin (Topical): May increase adverse/toxic effects of Erythromycin (Topical). Risk C: Monitor

Methoxsalen (Systemic): Photosensitizing Agents may increase photosensitizing effects of Methoxsalen (Systemic). Risk C: Monitor

Porfimer: Photosensitizing Agents may increase photosensitizing effects of Porfimer. Risk X: Avoid

Verteporfin: Photosensitizing Agents may increase photosensitizing effects of Verteporfin. Risk C: Monitor

Pregnancy Considerations

Animal reproduction studies have not been conducted with this combination. Refer to individual monographs.

Breastfeeding Considerations

It is not known if erythromycin or benzoyl peroxide are present in breast milk following topical application. Refer to individual monographs.

Pharmacokinetics (Adult Data Unless Noted)

See individual agents.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AR) Argentina: Acnepas E | Benzamycin | Erimicin | Kitacne p.b. | Peroxiderm e | Peroximicina;
  • (BE) Belgium: Benzadermine;
  • (BR) Brazil: Benzac Eritromicina | Benzagel eritromicina;
  • (CL) Chile: Benzac Plus | Benzamycin;
  • (CN) China: Benzamycin;
  • (CO) Colombia: Benzac kombi;
  • (DO) Dominican Republic: Benzac Plus;
  • (EC) Ecuador: Benzac kombi | Benzamycin;
  • (EG) Egypt: Acne benz | Acnidu;
  • (GB) United Kingdom: Benzamycin;
  • (GR) Greece: Erybenz | Zarcad;
  • (HK) Hong Kong: Benzamycin;
  • (IE) Ireland: Benzamycin;
  • (IL) Israel: Benzamycin;
  • (IN) India: Acne benz;
  • (KR) Korea, Republic of: Benzamycin;
  • (LB) Lebanon: Benzamycin;
  • (LU) Luxembourg: Benzadermine | Benzamycin;
  • (MX) Mexico: Benzac Plus | Benzamycin;
  • (PE) Peru: Benzac Plus;
  • (PR) Puerto Rico: Benzamycin | Erythromycin and benzoyl peroxide | Erythromycin benzoyl peroxide | Erythromycin/benzoyl peroxide;
  • (PY) Paraguay: Benzamycin | Erimicin;
  • (SG) Singapore: Benzamycin;
  • (TR) Turkey: Acnemix | Benzaderm | Benzamycin;
  • (ZA) South Africa: Benzamycine
  1. Benzamycin (erythromycin/benzoyl peroxide) [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; November 2020.
  2. Benzamycin (erythromycin/benzoyl peroxide) [product monograph]. Laval, Quebec, Canada: Bausch Health Canada Inc; September 2020.
  3. Dubina MI, Fleischer AB Jr. Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide. Arch Dermatol. 2009;145(9):1027-1029. doi:10.1001/archdermatol.2009.186 [PubMed 19770443]
  4. Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013;131(suppl 3):S163-S186. [PubMed 23637225]
  5. Erythromycin/benzoyl peroxide [prescribing information]. Bridgewater, NJ: Oceanside Pharmaceuticals; June 2019.
  6. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973. [PubMed 26897386]
Topic 8735 Version 166.0